KR102967623B1 - 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태 - Google Patents
액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태Info
- Publication number
- KR102967623B1 KR102967623B1 KR1020227008160A KR20227008160A KR102967623B1 KR 102967623 B1 KR102967623 B1 KR 102967623B1 KR 1020227008160 A KR1020227008160 A KR 1020227008160A KR 20227008160 A KR20227008160 A KR 20227008160A KR 102967623 B1 KR102967623 B1 KR 102967623B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- diffraction pattern
- ray powder
- powder diffraction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885977P | 2019-08-13 | 2019-08-13 | |
| US62/885,977 | 2019-08-13 | ||
| PCT/US2020/045847 WO2021030386A1 (en) | 2019-08-13 | 2020-08-12 | Salt and crystal forms of an activin receptor-like kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220052955A KR20220052955A (ko) | 2022-04-28 |
| KR102967623B1 true KR102967623B1 (ko) | 2026-05-21 |
Family
ID=72193669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227008160A Active KR102967623B1 (ko) | 2019-08-13 | 2020-08-12 | 액티빈 수용체 유사 키나아제 저해제의 염 및 결정 형태 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3442977T3 (fi) * | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| CA3117695A1 (en) | 2018-10-26 | 2020-04-30 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| WO2026161341A1 (en) * | 2025-01-21 | 2026-07-30 | Blueprint Medicines Corporation | Drug product formulations of fidrisertib |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3442977T3 (fi) * | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2020
- 2020-08-12 MX MX2022001741A patent/MX2022001741A/es unknown
- 2020-08-12 CN CN202080057092.0A patent/CN114222745B/zh active Active
- 2020-08-12 EP EP20761085.8A patent/EP4013757A1/en active Pending
- 2020-08-12 TW TW109127433A patent/TWI870440B/zh active
- 2020-08-12 US US17/633,440 patent/US20220281879A1/en active Pending
- 2020-08-12 JP JP2022508779A patent/JP7775186B2/ja active Active
- 2020-08-12 BR BR112022002597A patent/BR112022002597A2/pt unknown
- 2020-08-12 AU AU2020328534A patent/AU2020328534B2/en active Active
- 2020-08-12 UA UAA202200733A patent/UA130650C2/uk unknown
- 2020-08-12 WO PCT/US2020/045847 patent/WO2021030386A1/en not_active Ceased
- 2020-08-12 JO JOP/2022/0014A patent/JOP20220014A1/ar unknown
- 2020-08-12 CN CN202411831775.3A patent/CN119638704A/zh active Pending
- 2020-08-12 CA CA3146701A patent/CA3146701A1/en active Pending
- 2020-08-12 KR KR1020227008160A patent/KR102967623B1/ko active Active
-
2022
- 2022-02-09 MX MX2024014312A patent/MX2024014312A/es unknown
- 2022-02-09 IL IL290482A patent/IL290482A/en unknown
- 2022-02-14 CO CONC2022/0001450A patent/CO2022001450A2/es unknown
-
2025
- 2025-07-04 JP JP2025113638A patent/JP2025148406A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| Pharm. Tech. Japan, 2002, Vol. 18(10), pp. 1629-1644. |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI870440B (zh) | 2025-01-21 |
| KR20220052955A (ko) | 2022-04-28 |
| AU2020328534A1 (en) | 2022-03-17 |
| JP2022544272A (ja) | 2022-10-17 |
| JP2025148406A (ja) | 2025-10-07 |
| JOP20220014A1 (ar) | 2023-01-30 |
| MX2022001741A (es) | 2022-03-11 |
| US20220281879A1 (en) | 2022-09-08 |
| WO2021030386A1 (en) | 2021-02-18 |
| EP4013757A1 (en) | 2022-06-22 |
| CN114222745A (zh) | 2022-03-22 |
| AU2020328534B2 (en) | 2026-04-30 |
| UA130650C2 (uk) | 2026-04-08 |
| BR112022002597A2 (pt) | 2022-07-05 |
| CN119638704A (zh) | 2025-03-18 |
| JP7775186B2 (ja) | 2025-11-25 |
| TW202120509A (zh) | 2021-06-01 |
| CO2022001450A2 (es) | 2022-05-31 |
| CN114222745B (zh) | 2025-03-25 |
| MX2024014312A (es) | 2024-12-06 |
| CA3146701A1 (en) | 2021-02-18 |
| IL290482A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7775186B2 (ja) | アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態 | |
| JP6317320B2 (ja) | 上皮成長因子受容体キナーゼ阻害剤の塩 | |
| CN109970745A (zh) | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 | |
| ES2529105T3 (es) | Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso | |
| JP6816036B2 (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
| TW201920160A (zh) | 2-(5-(4-(2-嗎啉乙氧基)苯基)吡啶-2-基)-n-芐乙醯胺之固態形式 | |
| KR102847760B1 (ko) | 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도 | |
| US10561667B2 (en) | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | |
| CN119212996A (zh) | Pi3k抑制剂的结晶形式和盐及其制备方法和使用方法 | |
| WO2018149309A1 (zh) | 4-苯基噻唑衍生物的晶型及其制备方法 | |
| HK40117473A (en) | Salt and crystal forms of an activin receptor-like kinase inhibitor | |
| HK40069001B (en) | Salt and crystal forms of an activin receptor-like kinase inhibitor | |
| US20100179162A1 (en) | Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide | |
| HK40069001A (en) | Salt and crystal forms of an activin receptor-like kinase inhibitor | |
| BR112021001435A2 (pt) | formas cristalinas de um inibidor de lta4h | |
| US20240239796A1 (en) | Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof | |
| US20250188038A1 (en) | Crystalline forms of n-{[(s)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazol-1-yl][4-(trifluoromethyl)benzene | |
| US20250066346A1 (en) | Solid forms of a benzthiazole-piperazinyl-oxazole compound and methods of use thereof | |
| WO2025011618A9 (zh) | 噻唑并吡嗪类化合物的盐或其结晶及其应用 | |
| WO2025223483A1 (zh) | 并环含氮化合物、其晶型及其制备方法和用途 | |
| CN120344508A (zh) | 苯并恶嗪酮类化合物的结晶及其制备 | |
| CN116514796A (zh) | 3CLpro蛋白酶抑制剂的盐、晶型及其制备方法 | |
| CN121241043A (zh) | 埃维酰胺的晶型 | |
| JP2023524622A (ja) | 6-クロロ-7-(4-(4-クロロベンジル)ピペラジン-1-イル)-2-(1,3-ジメチル-1H-ピラゾール-4-イル)-3H-イミダゾ[4,5-b]ピリジンの塩及び多形体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |